Unknown

Dataset Information

0

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.


ABSTRACT: BACKGROUND:First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600?mg/m2), irinotecan (IRI: 200?mg/m2), and BEV (7.5?mg/m2)] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. Thus, a reduced dose of the CAP and IRI regimen in combination with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) may be more feasible than FOLFOXIRI+BEV, without compromising efficacy. METHODS:QUATTRO-II is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses of OX and IRI will be investigated as a safety lead-in. In Step 2, patients will be randomized to the recommended dose of either CAPOXIRI+BEV or FOLFOXIRI+BEV. Induction triplet chemotherapy plus BEV treatments will be administered for up to 4?months followed by fluoropyrimidine plus BEV maintenance. The primary endpoint is progression-free survival (PFS). The similarity in PFS between the two arms will be evaluated by observing whether the point estimate of hazard ratio (HR) for PFS falls between 0.80 and 1.25. Ensuring a 70% probability that the observed HR will be "0.8?

SUBMITTER: Miyo M 

PROVIDER: S-EPMC7376863 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.

Miyo Masaaki M   Kato Takeshi T   Yoshino Takayuki T   Yamanaka Takeharu T   Bando Hideaki H   Satake Hironaga H   Yamazaki Kentaro K   Taniguchi Hiroya H   Oki Eiji E   Kotaka Masahito M   Oba Koji K   Miyata Yoshinori Y   Muro Kei K   Komatsu Yoshito Y   Baba Hideo H   Tsuji Akihito A  

BMC cancer 20200723 1


<h4>Background</h4>First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m<sup>2</sup>), irinotecan (IRI: 200 mg/m<sup>2</sup>), and BEV (7.5 mg/m<sup>2</sup>)] was non-inferior to FOLFIRI+BEV as a second-line  ...[more]

Similar Datasets

| S-EPMC3078596 | biostudies-literature
| S-EPMC5922357 | biostudies-literature
| S-EPMC7819906 | biostudies-literature
| S-EPMC8712943 | biostudies-literature
| S-EPMC5814264 | biostudies-literature
| S-EPMC7877360 | biostudies-literature
| S-EPMC6156178 | biostudies-literature
| S-EPMC9271512 | biostudies-literature
| S-EPMC7640586 | biostudies-literature
| S-EPMC7376656 | biostudies-literature